References: slides 1-3
(Note: subject to formatting issues/possible link errors due to time lapse noting that research references remain constant over time - also can be viewed via pdf file previously published)
CA 125
Karen Eagle, Jonathan A. Ledermann Tumor Markers in Ovarian Malignancies The Oncologist, Vol. 2, No. 5, 324–329, October 1997
http://tinyurl.com/2wyvtf
Elvira M. Davelaar et al, Comparison of seven immunoassays for the quantification of CA 125 antigen in serum Jnl Clinical Chemistry.
1998;44:1417-1422.
http://www.clinchem.org/cgi/content/full/44/7/1417
Maurie Markman The Role of CA-125 in the Management of Ovarian Cancer The Oncologist, Vol. 2, No. 1, 6-9, February 1997
http://tinyurl.com/2gdsvk
Trope C, et al. Adjuvant chemotherapy for early-stage ovarian cancer: review of the literature. J Clin Oncol. 2007 Jul 1
0;25(20):2909-20.
Nayanah Siva Screening for Ovarian Cancer is Not Effective The Lancet Oncology Vol 8, Issue 9, Sept 2007; p764
TI Goonewardene, MR Hall, and GJ Rustin Management of asymptomatic patients on follow-up for ovarian cancer with rising CA-125 concentrations. Lancet Oncol, September 1, 2007; 8(9): 813-21
Mohan K. Tummala, MD William P. McGuire, MD Ovarian Cancer, (Editorial) CA-125 Addiction, and Informed Confusion: Much Ado About Less
Journal of Clinical Oncology, Vol 25, No 24 (August 20), 2007: pp 3570-3571 DOI:
10.1200/JCO.2007.11.9735
ER Woodward, et Multicentre/Country Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high-risk and population risk women is ineffective BJOG October 2007
http://www.blackwell-synergy.com/doi/abs/10.1111/j.1471-0528.2007.01499.x
Amy C. Dearking et al, Mayo Medical School, Department of Obstetrics and Gynecology, and Division of Biostatistics, Department of Health Science Research, Mayo Clinic, Rochester, Minnesota. How Relevant Are ACOG and SGO Guidelines for Referral of Adnexal Mass?
Obstetrics & Gynecology 2007;110:841-848 2007 by The American College of Obstetricians and Gynecologists
M.L. Hopkins et al Cancer Antigen 125 in ovarian cancer surveillance: a decision analysis model Current Oncology V. 14, No. 5 2007
Awareness/Communication:
Latini DM, et al CaPSURE Investigators.; discussion 831-2. The relationship between anxiety and time to treatment for patients with prostate cancer on surveillance J Urol. 2007 Sep;178(3 Pt 1):826-31; Ian M. Thompson and Donna P. Ankerst Prostate-specific antigen in the early detection of prostate cancer CMAJ Review - June 19, 2007; 176 (13). doi:10.1503/cmaj.060955.\
Tom Ferguson, MD with the e-Patients Scholars Working Group e-patients: how they can help us heal healthcare supported by Robert Wood Johnson Foundation
http://www.e-patients.net March 2007
Canadian Health Care Consensus Group: A Call to Action on Health Care Reform 2007
http://www.aims.ca/inside_chccg.asp?cmPageID=396#chno3
2007 Health Promotion Conference (International) Closing the Knowledge to Action Gap: Is Health Promotion and Health Education on the Verge of a Breakthrough?
http://www.ohpe.ca/ebulletin/index.php?option=com_content&task=view&id=8690&Itemid=78
Calhoun et al A comparison of ovarian cancer treatments analysis of utility assessments of ovarian cancer patients, at-risk populations, general populations and physicians Gynecologic Oncology 2004; 93:164-9 55
Access to Care:
S. Workman and O.E. Mann, QEII Health Science Centre, Halifax, Nova Scotia, Canada ‘No control whatsoever’: end-of-life care on a medical teaching unit from the perspective of family members 2007 Association of Physicians of Great Britain and Ireland March 12, 2007 ISSN 1460-2393
AR Kahn et al, Ovarian Cancer Treatment Patterns and Outcomes (OCTPO) Study, Factors Associated with Treatment Received for Ovarian Cancer , NAACCR Annual Conference Detroit, Michigan June 5, 2007
SM Crawford, Dr SM Crawford , Dept Medical Oncology and Gynaecology, Airedale General Hospital, West Yorkshire,, UK. Centralisation of
services for the management of ovarian cancer: arguments against BJOG: Intl Journal of Obstetrics and Gynaecology Vol 114 Issue 10
October 2007
Access to Care: 2-3
• S. Workman and O.E. Mann, QEII Health Science Centre, Halifax, Nova Scotia, Canada ‘No control whatsoever’: end-of-life care on a medical
teaching unit from the perspective of family members 2007 Association of Physicians of Great Britain and Ireland March 12, 2007 ISSN 1460-2393
• AR Kahn et al, Ovarian Cancer Treatment Patterns and Outcomes (OCTPO) Study, Factors Associated with Treatment Received for Ovarian Cancer , NAACCR Annual Conference Detroit, Michigan June 5, 2007
• SM Crawford, Dr SM Crawford , Dept Medical Oncology and Gynaecology, Airedale General Hospital, West Yorkshire,, UK. Centralisation of services for the management of ovarian cancer: arguments against BJOG: Intl Journal of Obstetrics and Gynaecology Vol 114 Issue 10 October 2007
•Richard G. Moore , Program in Women's Oncology, Depart Obstetrics and Gynecology, Women and Infants' Hospital, Brown University, Providence, RI How Do You Distinguish a Malignant Pelvic Mass From a Benign Pelvic Mass? Imaging, Biomarkers, or None of the Above JCO, Vol
25, No 27 (Sept 20), 2007: pp. 4159-4161
http://jco.ascopubs.org/cgi/content/full/25/27/4159
•Trimbos JB, Vergote I, Bolis G, Vermorken JB, Mangioni C, Madronal C, et al. Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European organisation for research and treatment of cancer-adjuvant chemotherapy in ovarian neoplasm trial.
J Natl Cancer Inst 2003;95(2):113–25
Kurt Christopher Giede*, Katharina Kieser, Jason Dodge, Barry Rosen ,University of Toronto, Canada Who should operate on patients with ovarian cancer? An evidence-based review ; Maurie Markman, Department of Gynecologic Medical Oncology, The University of Texas M.D. Anderson Cancer Center
Houston, TX Concept of Optimal Surgical Cytoreduction in Advanced Ovarian Cancer: A Brief Critique and a Call for Action JCO Comments and Controversies Vl 25 No. 27 September 20 2007
• Chan et al; Influence of the Gynecologic Oncologist on the Survival of Ovarian Cancer Patients Obstetrics & Gynecology 2007;109:1342-1350
© 2007 by The American College of Obstetricians and Gynecologists
• The Commonwealth Fund 2006 International Comparison: Access & Timeliness
http://www.commonwealthfund.org/snapshotscharts/snapshotscharts_show.htm?doc_id=409110
• L. Elit et al; Use of systemic therapy in women with recurrent ovarian cancer – Development of a national clinical practice guideline
Gynecologic Oncology doi: 10.1016/j.gyno.2007.03.025
Survival:
• Russell J. Schilder, MD, Matthew P. Boente, MD, Benjamin W. Corn, MD, Rochelle M. Lanciano, MD, Robert C. Young, MD, and Robert F. Ozols,
MD, PhD The Management of Early Ovarian Cancer Dept of Medical Oncology, Surgical Oncology, Radiation Oncology, Division of Medical
Science, Fox Chase Cancer Center, Philadelphia Feb 1995
http://www.cancernetwork.com/journals/oncology/o9502c.htm
C. Trope, et al, The Norwegian Radium Hospital, Oslo and Trondheim, Norway, Lund, Linkoping, Sweden and Odense, Denmark. Randomized
trial on adjuvant carboplatin versus no treatment in stage I high risk ovarian cancer by the Nordic Ovarian Cancer Study Group (NOCOVA) 1997
http://www.asco.org/prof/me/html/abstracts/gync/m_1260.htm56
Additional References:
•Ovarian Cancer: Screening, Treatment, and Followup. NIH Consensus Statement 1994 April 5-7;12(3): 1-30
http://www.medscape.com/govmt/NIH/1999/guidelines/NIH-ovarian/nih.ovarian-03.html
• AM Gonzalez-Angulo et al; Trends for inflammatory breast cancer: is survival improving? Oncologist, August 1, 2007; 12(8): 904-12., The University of Texas M. D. Anderson Cancer Center
• Charts Incident/mortality: Surveillance, Epidemiology, and the End Results (SEER) Program and the National Center for Health Statistics
http://seer.cancer.gov/
• H. E. Lambert et al, A randomized trial of five versus eight courses of cisplatin or carboplatin in advanced epithelial ovarian carcinoma* A North Thames Ovary Group Study Published Feb. 1997
http://annonc.oxfordjournals.org/cgi/reprint/8/4/327.pdf
• Dr William G. McGuire, Editorial Is It Time for Some New Approaches for Treating Advanced Ovarian Cancer? JNCI 2007
http://jnci.oxfordjournals.org/cgi/content/full/98/15/1024
David S. Alberts, A Unifying Vision of Cancer Therapy for the 21st Century ; JCO, Vol 17, No 11S (November Supplement), 1999: 13-21
http://jco.ascopubs.org/cgi/content/full/17/suppl_1/13#R8-0013
A Gompel, G Plu-Bureau : Correspondence: Ovarian cancer and hormone replacement therapy , The Lancet 2007; 370:932
•DOI:10.1016/S0140-6736(07)61436-6
Genetics:
Narod SA, Risch H, et al; .Oral contraceptives and the risk of hereditary ovarian cancer. Hereditary Ovarian Cancer Clinical Study Group N Engl J
Med. 1998 Aug 13;339(7):424-8 (full text article:
http://content.nejm.org/cgi/content/full/339/7/424)
Hereditary Ovarian Cancer Clinical Study Group (Risch/Narod et al) Oral contraceptives could be used as a means to prevent ovarian cancer in carriers of BRCA1 and BRCA2 mutations Lancet Oncol. 2007 Jan;8(1):26-34
http://www.thelancet.com/journals/lanonc/article/PIIS1470204506709834/abstract
PM. Steven Piver Review and Commentary The Oncologist: Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate The Oncologist, Vol. 1, No. 5, 326–330, October 1996
http://theoncologist.alphamedpress.org/cgi/content/full/1/5/326
Hermsen et al, No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study , British Journal of Cancer (2007) 96, 1335–1342. doi:10.1038/sj.bjc.6603725 www.bjcancer.com Published online 10 April 2007
P. J. C. Bresser et al; Who is prone to high levels of distress after prophylactic mastectomy and/or salpingo-ovariectomy? Annals of Oncology Advance Access originally published online on July 28, 2007 Annals of Oncology 2007 18(10):1641-1645; doi:10.1093/annonc/mdm274
2006 Lori d’Agincourt-Canning Genetic Testing for Hereditary Breast and Ovarian Cancer: Responsibility and Choice QUALITATIVE HEALTH
RESEARCH, Vol. 16 No. 1, January 2006 97-118 DOI: 10.1177/1049732305284002 in part supported by BC Cancer Agency
P. J. C. Bresser et al; Who is prone to high levels of distress after prophylactic mastectomy and/or salpingo-ovariectomy? Annals of Oncology Advance
Access originally published online on July 28, 2007 Annals of Oncology 2007 18(10):1641-1645; doi:
10.1093/annonc/mdm274
2006 Lori d’Agincourt-Canning Genetic Testing for Hereditary Breast and Ovarian Cancer: Responsibility and Choice QUALITATIVE HEALTH
RESEARCH, Vol. 16 No. 1, January 2006 97-118 DOI: 10.1177/1049732305284002 in part supported by BC Cancer Agency
2007 October 1: National Breast Cancer Coalition Survey Reveals That Heightened Breast Cancer Awareness Has Insufficient Impact on Knowledge/NBCC Calls on Presidential Candidates To Develop Strategies to Address the Most Prevalent Form of Cancer in Women
http://www.natlbcc.org/bin/index.asp?strid=985&btnid=2&depid=20
Anil K. Rustgi, Dept of Medicine (Gastrointestinal), Dept of Genetics, and Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania Genes & Dev. 2007 (October 19, 2007) The Genetics of hereditary colon cancer21: 2525-2538
http://www.genesdev.org
October 2007 Press Release: Vermillion Protein Biomarkers Help Detect Early-Stage Ovarian Cancer and Predict Survival
Data Presented at European Society of Gynecological Oncology Meeting –
http://money.cnn.com/news/newsfeeds/articles/prnewswire/AQW08931102007-1.htm
